The effects of postmenopausal hormone replacement therapy on hemostatic variables: a meta-analysis of 46 studies

References

• Hulley S, Grady D, Bush T, etal. Randomized trial of estrogen plus pro gestin for secondary prevention of coronary heart disease in postmenopausal women. J Am Med Assoc 1998;280:605–13
   PubMed Web of Science ®Google Scholar
• Meade TW, Berra A. Hormone replacement therapy and cardiovascular disease. Br Med Bull 1992;48:276–308
   PubMed Web of Science ®Google Scholar
• Nablusi AA, Folsom AR, White A, et al. Associa-tion of hormone replacement therapy with various cardiovascular risk factors in postmenopausal women. N Eng1J Med 1993;328: 1069–75
   Google Scholar
• Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment ofthe epidemiologic evidence. Prey Med 1992;20:47–53
   Google Scholar
• Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausalwomen. Ann Intern Med 1992:117: 1016–37
   PubMed Web of Science ®Google Scholar
• Falkeborn M, Persson I, Terent A, etal. Hormone replacement therapy and the risk of stroke. Arch Intern Med 1993;153:1201–9
   PubMed Web of Science ®Google Scholar
• Grodstein F, Stampfer MJ, Manson JA, et al. Post-menopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335: 453–61
   PubMed Web of Science ®Google Scholar
• Wilcox JG, Hwang J, Hodis HN, et al. Cardio-protective effects of individual conjugated equine estrogens through their possible modulation of insulin resistance and oxidation of low-density lipoprotein. Fertil Steril 1997;67:57–62
   PubMed Web of Science ®Google Scholar
• Gerhard M, Ganz P. How do we explain the clini-cal benefits of estrogen? Circulation 1995;92:5–8
   PubMed Web of Science ®Google Scholar
• Daly E, Vessey MP, Hawkins MM, et al. Risk of venous thromboembolism, in users of hormone replacement therapy. Lancet 1996;348:977–80
   PubMed Web of Science ®Google Scholar
• Jick H, Derby LE, Myers MW, et al. Risk of hospital admission for idiopathic venous thrombo-embolism in users of hormone replacement therapy. Lancet 1996;348:981–3
   PubMed Web of Science ®Google Scholar
• Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348:983–7
   PubMed Web of Science ®Google Scholar
• Oger E, Scarabin PY. Assessment of the risk for venous thromboembolism among users of hormone replacement therapy. Drugs Aging 1999; 14:55–61
   PubMed Web of Science ®Google Scholar
• Alkjaersig N, Fletcher AP, De Ziegler D, et al. Blood coagulation in postmenopausal women given estrogen treatment: comparison of trans-dermal and oral administration. J Lab Clin Med 1988;111:224–8
   PubMedGoogle Scholar
• Wilhelmsen L, Svardsudd K, Korsan-Bengsten K, et al. Fibrinogen as a risk factor for stroke and myo-cardial infarction. N Eng1J Med 1984;311: 501–5
   Google Scholar
• Meade TW, Ruddock V, Stirling Y, et al. Fibrinolytic activity, clotting factors and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993;342: 1076–9
   PubMed Web of Science ®Google Scholar
• Folsom AR, Wu KK, ShaharE, etal. Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery athero-sclerosis. Arteriosder Thromb 1993;13:1829–36
   PubMed Web of Science ®Google Scholar
• Wiman B, Hamsten A. The fibrinolytic enzyme system and its role in the etiology of thrombo-embolic disease. Semin Thromb Hemost 1990; 16:207–16
   PubMed Web of Science ®Google Scholar
• Ridker PM, Vaughan DE, Stampfer MJ, et al. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993;341: 1165–8
   PubMed Web of Science ®Google Scholar
• Allaart CF, Briet E. Familial venous thro mb op hilia. In Bloom AL, Forbes CD, Thomas DP, TuddenhamEGD, eds. Haemostasis and Thrombosis. Third edn., Edinburgh: Churchill Livingstone, 1994:1349–60
   Google Scholar
• Bauer KA, Broekmans AW, Bertina RM, et al. Hemostatic enzyme generation in the blood of patients with hereditary protein C deficiency. Blood 1988;71:1418–26
   PubMedGoogle Scholar
• Miller GJ, Bauer KA, Barzegar S, et al. Increased activation of the hemostatic system in men at high risk of fatal coronary heart disease. Thromb Haemost 1996;75:767–71
   PubMedGoogle Scholar
• Meade TW. Hormone replacement therapy and hemostatic function. Thromb Haemost 1997;78: 765–9
   PubMed Web of Science ®Google Scholar
• Lowe GDO, Rumley A, Woodward M, et al. Epidemiology ofcoagulation factors, inhibitors and activation markers. The Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use. Br J Haematol 1997;97:775–84
   Google Scholar
• Petitti DB. Meta-analysis, Decision Analysis and Cost-effectiveness Analysis. New York: Oxford University Press, 1994:115–23
   Google Scholar
• Bush TL, Cowan LD, Barrett-Connor E, et al. Estrogen use and all-cause mortality. J Am Med Assoc 1983; 249:903–6
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Wingard DL, Criqui MH. Postmenopausal estrogen use and heart disease risk factors in the 1980s. J Am Med Assoc 1989;261: 2095–100
   Google Scholar
• Acs N, Szekics B, Nidasy GL, et al. The effects of ovariectomy and oestrogen replacement on small artery biomechanics in the rat. BrJ Obstet Gynaecol 1999;106:148–54
   PubMedGoogle Scholar
• Kannel WB, Wolf PA, Castelli WP, D 'Agostino RR. Fibrinogen and risk of cardiovascular disease: The Framingham Study. JAm Med Assoc 1987;258: 1183–6
   Google Scholar
• Scarabin PY, Plu-Bureau G, Bara L, et al. Hemo-static variables and menopausal status: influence of hormone replacement therapy. Thromb Haemost 1993;70:584–7
   PubMed Web of Science ®Google Scholar
• Morrissey JH. Tissue factor interactions with factor VII: measurement and clinical significance of factor VIIa in plasma. Blood Coag Fibrinolysis 1995;6: S14—S19
   Google Scholar
• Hoffman C, Miller R, Hultin M. Correlation of factor VII activity and antigen with cholesterol and triglycerides in healthy young adults. Arterioscler Thromb 1992;12:267–70
   Google Scholar
• Carvalho de Sousa J, Azevedo J, Soria C, et al. Factor VII hyperactivity in acute myocardial thrombosis. A relation to the coagulation activa-tion. Thromb Res 1988;51:315–22
   Google Scholar
• Meade TW, Imeson JD, Haines AP, et al. Meno-pausal status and hemostatic variables. Lancet 1986; 1:22–4
   PubMedGoogle Scholar
• Denson KWE. The ratio of factor VIII-related antigen and factor VIII biologic activity as an index of hypercoagulability and intravascular clotting. Thromb Res 1977;10:107–19
   PubMedGoogle Scholar
• Bloom AL, Giddings JC, Wilks CJ. Factor VIII on the vascular intima: possible importance in haemostasis and thrombosis. Nature New Biology 1973;241:217–19
   Google Scholar
• Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor I and atherothrombosis. Thromb Haemost 1993;70:138–43
   PubMed Web of Science ®Google Scholar
• Hamsten A, Walldius G, Szamosi A, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987;2:3–9
   PubMed Web of Science ®Google Scholar
• Jansson JH, Olofss on BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concen-tration on long-term mortality in patients with coronary artery disease: a 7 year follow up. Circula-tion 1993;88:2030–4
   PubMed Web of Science ®Google Scholar
• Shahar E, Folsom AR, Salomaa VV, et al. Relation of hormone-replacement therapy to measures of plasma fibrinolytic activity. Circulation 1996;93: 1970–5
   PubMed Web of Science ®Google Scholar
• Lee AJ, Lowe GDO, Smith WCS, Tunstall-Pedoe H. Plasma fibrinogen in women: relationships with oral contraception, the menopause and hormone replacement therapy. Br J Haematol 1993;83: 616–21
   Google Scholar
• Gilabert J, Estelles A, Cano A, et al. The effect of estrogen replacement therapy with or without pro-gesto gen on the fibrinolytic system and coagulation inhibitors in postmenopausal status. Am J Obstet Gynecol 1995;173:1849–54
   PubMed Web of Science ®Google Scholar
• Kessler CM, Szymanski LM, Shamsipour Z, et al. Estrogen replacement therapy and coagulation: relationship to lipid and lipoprotein changes. Obstet Gynecol 1997;89:326–31
   PubMed Web of Science ®Google Scholar
• DeSouza CA, Stevenson ET, Davy KP, et al. Plasma fibrinogen levels in healthy postmenopausal women: physical activity and hormone replace-ment status. J Gerontol 1997;52A:M294–8
   Google Scholar
• Saleh AA, Dorey LG, Dombrowski MP, et al. Thrombosis and hormone replacement therapy in postmenopausalwomen. Am J Obstet Gyneco11993; 169:1554–7
   PubMedGoogle Scholar
• Gebara OCE, Mittleman MA, Sutherland P, et al. Unstable angina/myocardial infarction/athero-sclerosis: association between increased estrogen status and increased fibrinolytic potential in the Framingham OfEpring Study. Circulation 1995;91: 1952–8
   PubMed Web of Science ®Google Scholar
• Conard J, Gompel A, Pelissier C, et al. Fibrinogen and plasminogen modifications during oral estradiol replacement therapy. Fertil Steril 1997;68: 449–53
   PubMedGoogle Scholar
• Frohlich M, Schunkert H, Hense HW, et al. Effects of hormone replacement therapies on fibrinogen and plasma viscosity in postmenopausal women. Br J Haematol 1998;100:577–81
   PubMedGoogle Scholar
• Chen FP, Lee N, Wang CH, et al. Effects of hormone replacement therapy on cardiovascular risk factors in postmenopausal women. Fertil Steril 1998;69:267–73
   PubMed Web of Science ®Google Scholar
• Sporrong T, Mattson LA, Samsioe G, etal. Hemo-static changes during continuous o estradiol-p ro gesto gen treatment o f postmeno pausal wo men. Br J Obstet Gynaecol 1990;97:939–44
   Google Scholar
• Lindoff C, Peterson F, Lecander I, et al. Trans-dermal estrogen replacement therapy: beneficial effects on hemostatic risk factors for cardiovascular disease. Maturitas 1996;24:43–50
   PubMed Web of Science ®Google Scholar
• Conard J, Samama M, Basdevant A, etal. Differen-tial AT III-response to oral and parenteral adminis-tration of 1713-estradiol. Thromb Haemost 1983; 49:252
   PubMed Web of Science ®Google Scholar
• Folsom AR, Wu KK, Davis CE, et al. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis 1991;91:191–205
   PubMed Web of Science ®Google Scholar
• Kro on UB, Tengborn L, Rita H, Bäckström AC. The effects of transdermal oestradiol and oral progestagens on haemostasis variables. Br J Obstet Gynaecol 1997 ;104(Suppl 16):32–37
   PubMedGoogle Scholar
• Koh KK, Mincemoyer R, Bui MN, etal. Effects of hormone replacement therapy on fibrinolysis in postmenopausal women. N Eng1J Med 1997;336: 683–9
   PubMed Web of Science ®Google Scholar
• Chetkowski RJ, Meldrum DR, Kenneth MD, etal. Biologic effects of transdermal estradiol. N Engl J Med 1986;314:1615–20
   PubMed Web of Science ®Google Scholar
• Notelovitz M, Kitchens C, Ware M, et al. Combi-nation estrogen and progestogen replacement ther-apy does not adversely affect coagulation. Obstet Gynecol 1983;62:596–600
   PubMed Web of Science ®Google Scholar
• Notelovitz M, Kitchens CS, Ware MD. Coagula-tion and fibrinolysis in estrogen-treated surgically postmenopausal women. Obstet Gynecol 1984;63: 621–5
   Google Scholar
• Meilahn EN, Cauley JA, Tracy RP, et al. Associa-tion of sex hormones and adiposity with plasma levels of fibrinogen and PAI-1 in postmenopausal women. Am J Epidemiol 1996;143:159–66
   PubMedGoogle Scholar
• Caine YG, Bauer KA, Barzegar S, et al. Coagula-tion activation following estrogen administration to postmenopausal women. Thromb Haemost 1992; 68:392–5
   PubMed Web of Science ®Google Scholar
• Cushman M, Yanez D, Psaty BM, etal. Association of fibrinogen and coagulation factors VII and VIII with cardiovascular risk factors in the elderly. Am J Epidemiol 1996;143:665–76
   PubMedGoogle Scholar
• Kroon UB, Silfverstolpe G, Tengborn L. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Thromb Haemost 1994;71:420–3
   Google Scholar
• The Writing Group for the Estradiol Clotting Factors Study. Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: a 1-year, double-blind, placebo-controlled study. Thromb Haemost 1996;75:476–80
   PubMed Web of Science ®Google Scholar
• Brussaard HE, Gevers Leuven JA, Frölich M, etal. Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM. Diabetologia 1997;40:843–9
   Google Scholar
• The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausalwo men. JAm Med Assoc 1995;273:199–208
   PubMed Web of Science ®Google Scholar
• van der Mooren MJ, Demacker PNM, Thomas CMG, et al. A 2-year study on the beneficial effects of 1713-oestradiol—dydrogesterone therapy on serum lipoproteins and Lp(a) in postmenopausal women: no additional unfavourable effects of dydrogesterone. Eur J Obstet Gynecol 1993;52: 117–23
   PubMed Web of Science ®Google Scholar
• Scarabin PY, Vissac AM, Kirzin JM, et al. Popula-tion correlates of coagulation factor VII. Impor-tance of age, sex and menopausal status as determinants of activated factor VII. Arterioscler Thromb Vasc Biol 1996;16:1170–6
   Google Scholar
• Fox J, George J, Newton JR., et al. Effect of trans-dermal oestradiol on the hemostatic balance of menopausal women. Maturitas 1993;18:55–64
   Google Scholar
• Boschetti C, Cortellaro M, Nencioni T, et al. Short- and long-term effects of hormone replace-ment therapy (transdermal estradiol vs oral conju-gated equine estrogens, combined with medroxyprogesterone acetate) on blood coagula-tion factors in postmenopausalwomen. Thromb Res 1991;62:1–8
   PubMedGoogle Scholar
• Pinto S, Bruni V, Rosati D, etal. Effects of estrogen replacement therapy on thrombin generation. Thromb Res 1997;85:185–93
   PubMedGoogle Scholar
• Conard J, Basdevant A, Thomas JL, et al. Cardio-vascular risk factors and combined estro- gen—pro gestinreplacementtherapy:aplacebo-controlled study with nomegestrol acetate and estradiol. Fertil Steril 1995;64:957–62
   PubMed Web of Science ®Google Scholar
• Marchesoni M, Dal Pozzo M, Dal Magro M, et al. Transdermal estroprogestins versus transdermal estrogen plus oral dihydrogesterone replacement in menopause. J Endocrinol Invest 1996;19:268–72
   PubMedGoogle Scholar
• Medical Research Council's General Practice Research Framework. Randomised comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in women with hysterectomy. Br Med J 1996;312:473–8
   Google Scholar
• Corsaut MJ, Bierma TJ, Kasa RM. Factor VIII:C relationships to selected lipids, age, and gender in healthy adults. Am J Med Sci 1990;300:83–7
   Google Scholar
• Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, etal. Effects of oral and transdermal estrogen/progester-one regimens on blood coagulation and fibrinolysis in postmenopausal women: a randomized con-trolled trial. Arterioscler Thromb Vasc Biol 1997;17: 3071–8
   PubMed Web of Science ®Google Scholar
• Bissonette F, Lussier-Cacan S, Fugere P, Berube S. Metabolic effect of two hormonal preparations in postmenopausal women. Maturitas 1997;27: 275–84
   PubMedGoogle Scholar
• Van der Mooren MJ, Demacker PNM, Thomas CMG, Rolland R. Beneficial effects on serum lipoproteins by 1713-o estradiol—dydro gesterone therapy in postmenopausal women; a prospective study. Eur J Obstet Gynecol 1992;47:153–60
   PubMed Web of Science ®Google Scholar
• Estelles A, Cano A, Falco C, et al. Lipoprotein(a) levels and isoforms and fibrinolytic activity in postmenopause — influence of hormone replace-ment therapy. Thromb Haemost 1999;81:104–10
   PubMedGoogle Scholar
• Manolio T, Furberg C, ShemanskiL, et al. Associa-tions of postmenopausal estrogen use with cardio-vascular disease and its risk factors in older women. Circulation 1993;88:2163–71
   PubMed Web of Science ®Google Scholar
• Egarter C, Geurts P, Bo schitsch E, etal. The effects of estradiol valerate plus medroxyprogesterone acetate and conjugated estrogens plus medro-gestone on climacteric symptoms and metabolic variables in perimenopausal women. Acta Obstet Gynecol Scand 1996;75:386–93
   PubMed Web of Science ®Google Scholar
• Salomaa V, Rasi V, Pekkanen J, et al. Association of hormone replacement therapy with hemostatic and other cardiovascular risk factors. Arterioscler Thromb Vasc Biol 1995;15:1549–55
   PubMed Web of Science ®Google Scholar
• Hänggi W, Lippuner K, Ries en W, et al. Long term influence of different postmenopausal hormone replacement regimens on serum lipids and lipo-protein(a): a randomised study. BrJ Obstet Gynaecol 1997;104:708–17
   Google Scholar
• Varma TR, Patel RH, Rosenberg D. Effect of hormone replacement therapy on anti-thrombin III activity in post menopausalwomen. IntJ Gynecol Obstet 1986;24:69–73
   Google Scholar
• van Wersch JWJ, Ubachs JMH, van den Ende A, van Enk A. The effect of two regimens of hormone replacement therapy on the hemostatic profile in postmenopausal women. Eur J Clin Chem Clin Biochem 1994;32:449–53
   PubMedGoogle Scholar
• Corradi A, Lazzaro F, Cofrancesco E, et al. Pre-operative plasma levels of prothrombin fragment 1 + 2 correlate with the risk of venous thrombosis after elective hip replacement. Acta Orthop Belg 1999;65:39–43
   PubMedGoogle Scholar
• Moss AJ, Goldstein RE, Marder VJ, et al. Thrombogenic factors and recurrent coronary events. Circulation 1999;99:2517–22
   PubMedGoogle Scholar
• Dangas G, Badimon JJ, Smith DA, et al. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. JAm Coll Cardiol 1999;33:1294–304
   PubMed Web of Science ®Google Scholar
• Brown NJ, Agirbasli M, Vaughan DE. Compara-tive effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Hypertension 1999;34: 285–90
   Google Scholar
• Saks ela O, Rifkin DB. Cell-associated plasminogen activation: regulation and physiologic functions. Annu Rev Cell Biol 1988;4:93–126
   PubMedGoogle Scholar
• Chomiki N, Henry M, Alessi MC, et al. Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls. Thromb Haemost 1994;72:44–53
   PubMed Web of Science ®Google Scholar
• Schneiderman J, Sawdey MS, Keeton MR, et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992;89;6998–7002
   PubMed Web of Science ®Google Scholar
• Hamsten A, Wiman B, deFaire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myo-cardial infarction. N EnglJ Med 1985;313:1557–63
   PubMed Web of Science ®Google Scholar
• Maresca G, Di Blasio A, Marchioli R, Di Minno G. Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update. Arterioscler Thromb Vasc Biol 1999;19:1368–77
   PubMed Web of Science ®Google Scholar